)
Visual21 Nov 2025
Data center suppliers
Merck & Co (MRK) investor relations material
Merck & Co Jefferies London Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Jefferies London Healthcare Conference 2025 summary20 Nov, 2025
Recent milestones and business development
Multiple milestones achieved, including the acquisition of Cidara and positive phase III HIV data for islatravir/doravirine.
Keytruda subcutaneous formulation approved in Europe, and Winrevair Cadence phase II data released.
Cidara acquisition targets high-risk populations for influenza with a long-acting, strain-agnostic antiviral showing 76% efficacy in phase II.
U.S. FDA requested expansion of Cidara's phase III to include older adults without comorbidities, reflecting strong regulatory interest.
Cidara's asset aligns with government pandemic prevention strategies and may attract BARDA support.
Product pipeline and clinical development
Winrevair shows transformative impact in PAH, with growing adoption in advanced and dual therapy patients; 500+ new U.S. patients monthly.
Cadence phase II data promising for CPC PH, a rare disease with no current treatments; phase III planning underway.
EyeBio acquisition brings trispecific immune assets for diabetic macular edema and wet AMD, addressing unmet needs for 40% of patients unresponsive to anti-VEGFs.
MK-3000 and Tiespectus from EyeBio are advancing rapidly, with phase III DME readout expected next year.
Enlicitide, an oral PCSK9, delivers biologic-like efficacy with 60% LDL reduction; food effect not a barrier, and broad access strategy planned.
Oncology and HIV portfolio highlights
Sac-TMT ADC aims for broad utility across multiple tumor types, with 15 phase III trials ongoing and focus on community oncologist adoption.
Tolerability and ability to keep patients on therapy seen as key to improving overall survival in sac-TMT trials.
Islatravir/doravirine daily regimen shown non-inferior to Biktarvy, with PDUFA date in April; weekly oral and monthly PrEP options in late-stage development.
Monthly oral PrEP option preferred by a third of surveyed at-risk individuals, offering privacy and convenience.
HIV franchise seen as a multi-billion dollar opportunity, with underappreciated market potential.
How will Cidara's strain-agnostic nature drive adoption?
Define CpcPH Phase III endpoints with the FDA.
Enlicitide access without CV outcomes data?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Merck & Co earnings date
Q4 20253 Feb, 2026
Next Merck & Co earnings date
Q4 20253 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Over 130 Years of Experience in Healthcare
Merck & Co., commonly known as Merck, is a global pharmaceutical company that specializes in the development and manufacturing of prescription drugs, vaccines, biological therapies, and animal health products. With a storied history dating back over a century, Merck has established itself as a leading player in the healthcare industry. The company's portfolio of products spans various therapeutic areas, including cardiovascular, oncology, infectious diseases, and more.
In business for over a century
Since its establishment in 1891, Merck has played a significant role in advancing medical research and innovation and has a long history of notable contributions to healthcare. They have developed antibiotics like streptomycin, vaccines for diseases such as mumps and HPV, and antiretroviral therapies for HIV/AIDS treatment. Their advancements in cardiovascular medications and statins have significantly impacted heart disease management.
The company today
Today the company focuses on the development, manufacturing, and distribution of a diverse range of prescription drugs, vaccines, and biological therapies. With a commitment to scientific rigor, research, and providing products and medication that improve the lives of ill patients, Merck strives to address various health challenges and contribute to the well-being of individuals globally. Merck is far from being alone when it comes to publicly traded pharmaceutical companies, and some companies that operate in the same space include names such as Pfizer and Eli Lilly.
A diverse portfolio of medications
Merck & Co. develops and manufactures a wide range of medications. Their portfolio of products includes medications for cardiovascular diseases, such as hypertension and hyperlipidemia, as well as anticoagulants and antiplatelet agents. They also offer therapeutics for infectious diseases, including antibiotics, antifungals, and antiviral drugs. In oncology, Merck provides targeted therapies and immunotherapies for different types of cancer. Additionally, they offer medications for diabetes management, respiratory diseases, autoimmune disorders, and more. The company’s flagship medication is Keytruda, which enhances the body’s ability to fight certain types of cancers.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage